Short-term intensive treatment for acute myelogenous leukemia (excluding M3 subtype) in adults

T. Ino, T. Yamaguchi, M. Tsuzuki, T. Nomura, H. Miyazaki, F. Maruyama, H. Kojima, M. Okamoto, T. Matsui, K. Ezaki, M. Hirano

Research output: Contribution to journalArticlepeer-review


Thirty-two adults (median age 48 years) with acute myelogenous leukemia (excluding M3) have been treated with short-term intensive therapy (M90 therapy). After induction therapy with daunorubicin, cytosine arabinoside (araC), 6-mercaptopurine, prednisolone, mitoxantrone (MIT) and etoposide (VP16), three regimens of post-induction chemotherapy were conducted as short an intercycle time as possible. The first regimen was with MIT and VP16, the second with behenoyl-araC and aclarubicin and the third with VP16, araC, vincristine and vinblastine. No further therapy was given. Complete remission was achieved in 24 (75%) of 32 patients and 24% of all patients were projected to remain free of disease at 5 years. The median duration of the entire therapy was 120 days with a range of 95 to 157 days. Post-induction regimens resulted in severe myelosuppression and their toxicity included treatment-related death in one patient. The treatment results of this short-term therapy were comparable to a former treatment protocol, M84 therapy with a median duration of the entire treatment therapy of 515 days. To confirm the advantages of such short-term therapy, prospective randomized comparisons with conventional post-induction therapy may be required.

Original languageEnglish
Pages (from-to)209-216
Number of pages8
Journal[Rinshō ketsueki] The Japanese journal of clinical hematology
Issue number3
Publication statusPublished - 03-1997

All Science Journal Classification (ASJC) codes

  • Medicine(all)


Dive into the research topics of 'Short-term intensive treatment for acute myelogenous leukemia (excluding M3 subtype) in adults'. Together they form a unique fingerprint.

Cite this